FDA Advisory Panel recommends approval of Orkambi to treat people with cystic fibrosis ages 12 and older who have two copies of the F508del mutation
The Food and Drug Administration's ( FDA ) Pulmonary-Allergy Drugs Advisory Committee ( PADAC ) voted 12 to 1 to recommend that the FDA approve Orkambi ( Lumacaftor / Ivacaftor ) for use in people wit ...
read article